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Background and Purpose: Low-dose topiramate (TPM) monotherapy has recently been found effective for 
seizure control in newly diagnosed epilepsy. In higher dosages, TPM has been associated with relatively high 
rates of adverse cognitive effects; similar side effects have been seen after rapid titration or polytherapy. 
However, its cognitive effects during low-dose monotherapy have not been established. We evaluated the 
cognitive effects of low-dose TPM compared with oxcarbazepine (OXC), a drug that does not appear to affect 
cognitive function. 
Methods: Cognitive tests and subjective complaints of 30 patients with low-dose TPM monotherapy (50-200 
mg/day) were retrospectively compared with those of 30 patients with OXC monotherapy at 1 year of medication. 
The two groups did not differ with respect to epilepsy-relevant variables, nor on baseline neuropsychological tests.
Results: The TPM group showed a significant difference in the performance of delayed word recall (P<0.05), 
backward digit span (P<0.01), and verbal fluency (P<0.05) compared with the OXC group. The TPM group showed 
worse performances of digit span and verbal fluency. The OXC group showed better performances of delayed word 
recall. The incidence of cognitive complaints was higher in the TPM group (50%) than in the OXC group (20%) 
(P< 0.05). These cognitive effects shown in the TPM group were dose-related. The cognitive dysfunction was trivial with 
patients taking 50 mg/day TPM.
Conclusions: Even at low-dose, TPM has a negative effect on working memory and verbal fluency compared 
with OXC. It can be demonstrated at 1 year of treatment.
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INTRODUCTION
A significant proportion of patients with epilepsy are 
at increased risk of cognitive impairment. A variety of 
factors contribute to their cognitive dysfunction.
1 In 
particular, antiepileptic drugs (AEDs) can cause adverse 
cognitive effects.
2,3 AEDs exert a dose-dependent effect 
on cognitive functioning, and AED polytherapy can 
result in even more striking adverse cognitive effects. 
However, the differential effects of AED monotherapy 
are less clear.
3
Low-dose topiramate (TPM) monotherapy has recently 
been found to be effective for seizure control in partial 
or generalized epilepsy.
4,5 However, TPM has been 
associated with a high incidence of cognitive impairment 
(ranging between 11% and 20%) in patients with 
refractory epilepsy who have received polytherapy.
6,7 The 
major cognitive complaints are impaired attention / con-
centration, memory deficits, slow thinking, and word- Kim SY, et al. Cognitive Effects of Low-dose Topiramate in Epilepsy Patients 
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finding difficulties.
6-14 These effects relate to higher 
dosages, rapid titration, and polytherapy.
2,3,6 When TPM 
monotherapy is prescribed at dosages of 25~500 mg/day, 
the cognitive impairments are usually mild to moderate 
and the incidence is less than 10%.
4,5 Although it is 
reasonable to assume that TPM would cause fewer 
cognitive deficits at lower dosages, the magnitude of 
such effects has not been established, and further 
neuropsychological studies are needed.
Oxcarbazepine (OXC) is a novel AED that is 
chemically related to carbamazepine and is approved for 
initial or add-on treatment of partial seizures.
15 Two 
European studies have evaluated its cognitive effects in 
adult epilepsy patients. In one of these, newly diagnosed 
patients received OXC or other AEDs as a monotherapy 
for 4 months. Compared with baseline, OXC-treated 
patients improved in 1 of 20 cognitive tasks and 
worsened in none. Patients treated with carbamazepine, 
valproic acid, phenobarbital, or phenytoin (PHT) mono-
therapy had similar results.
16 The other study was a 
double-blind comparison of OXC with PHT mono-
therapy in newly diagnosed patients,
17 in which no 
differences between OXC and PHT were detected in any 
of the seven cognitive variables measured at any of the 
time points. We have also previously investigated the 
cognitive effects of OXC in epilepsy patients using neuro-
psychological tests and event-related potentials, and did 
not find any negative effects of OXC on cognition after 
1 year of treatment.
18 The results of these studies suggest 
that OXC does not affect cognitive function in epilepsy 
patients. 
The aim of this study was to identify cognitive effects 
of low-dose TPM compared with OXC in epilepsy 
patients treated with these drugs for 1 year. A variety of 
cognitive tests and subjective complaints were compared 
at baseline and 1 year of medication between two 
groups.
MATERIALS AND METHODS
1. Subjects
Our epilepsy clinic began to study the cognitive 
effects of AEDs on epilepsy patients in 2000. We 
routinely performed cognitive evaluations (i.e., records 
of subjective complaints and neuropsychological tests) 
after AED was taken. The severity of subjective com-
plaints after medication was divided into four grades: 
Grade 0 meant no symptoms; Grade 1 meant mild and 
intermittent cognitive problems, usually of no conse-
quence; Grade 2 meant moderate and steady cognitive 
deficits, sometimes creating discomfort; and Grade 3 
equated with severe cognitive deficits such that medi-
cation had to be discontinued. The neuropsychological 
tests were scheduled to perform three times on each 
subject: at baseline, at 1 year, and after 3 years of medi-
cation. EEGs were performed on all patients before 
entering the study and also at the time of the second and 
third neuropsychological test. The EEGs included hyper-
ventilation, photic stimulation, and sleep provocation and 
they were interpreted by the same epileptologist who 
was blinded to the clinical data. MRI of the brain was 
performed once on each patient during the study. 
More than 600 cases were enrolled in our epilepsy 
neuropsychological database. From this collection of 
documented cases we selected subjects if they matched 
all of the following criteria: (1) TPM or OXC mono-
therapeutic patients who were undergoing follow-up 
cognitive evaluations at 1 year, (2) TPM dosage less 
than 200 mg/day, (3) either newly diagnosed epilepsy or 
had epilepsy that had not been treated with AEDs for 
more than 6 months, (4) no progressive neurological 
disorders, head injury, mental retardation, alcohol or 
drug abuse, ongoing use of any central-acting medi-
cations, severe psychiatric problems, or other severe 
medical disorders, and (5) no cognitive complaints at 
baseline. 
In total, 30 patients for TPM therapy and 38 for OXC 
met the above criteria, with 30 of the latter patients 
being age-matched with the TPM group to form a 
comparison group. Patient characteristics are listed in 
Table 1. Daily TPM dosages at 1 year were 50 mg for 
9, 75 mg for 10, 100 mg for 8, and 200 mg for 3 
patients (mean dose: 87 mg). Daily OXC dosages at 1 
year were 600 mg for 10, 750 mg for 1, 900 mg for 17, 
1,200 mg for 1, and 1,500 mg for 1 patient (mean dose: 
825 mg). Both groups showed a significant decrease of Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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TPM (n=30) OXC (n=30) Significance*
Age, y, mean (range)
Sex, % male
31.6 (15~59)
40
32.6 (14~58)
43
NS
†
NS
Education, %
Graduate primary or middle school
Graduate high school or college
30
70
30
70
NS
NS
Seizure type, %
Partial
Generalized
53
47
73
27
NS
NS
Duration of epilepsy, y, mean (range)
Newly diagnosed epilepsy, within 3 months, %
Presence of brain pathology in MRI, %
Dose at 1 year, mg/day, mean (range)
3.2 (0.1~20)
57
13
87 (50~200)
3.3 (0.1~20)
60
23
825 (600~1,500)
NS
NS
NS
Seizure rate for recent 3 months, seizures / month
Baseline
At 1 year
1.6 (0.3~8)
0.3
§ (0~3)
1.8 (0.3~20)
0.5
§ (0~8)
NS
NS
Abnormality of EEG, %
Baseline
At 1 year
57
20
§
50
20
‡
NS
NS
TPM; topiramate, OXC; oxcarbazepine
*Fisher exact tests and t tests for independent samples (two-sided), 
†Nonsignificant, P>0.05, 
‡P<0.05, 
§P<0.01, comparing with baseline.
Table 1. Patient characteristics
their monthly seizure rate and EEG abnormalities after 
AED medication. The groups did not differ with respect 
to epilepsy-relevant variables.
2. Neuropsychological tests
Cognitive tests were administered in a sound-attenuated, 
temperature-controlled room. All the tests were per-
formed by a single examiner. According to the literature 
and our own clinical experience, we selected a few 
cognitive measures as being particularly sensitive to 
AED-induced cognitive impairment. We assessed memory 
function through list learning, immediate and delayed 
word recall, word recognition, and visual reproduction 
based on the Memory Assessment Scale, obtained from 
Psychological Assessment Resources.
19 We assessed 
attention deficit by using digit spans (forward and 
backward) from the Wechsler Memory Scale-Revised.
20 
We examined attention, visuomotor tracking abilities, 
and mental flexibility by using the Trail Making Test 
(TMT) from the Halstead-Reitan Battery.
21 We studied 
verbal fluency by using semantic fluency tests from the 
BDAE-3 (Boston Diagnostic Aphasia Examination-Third 
Edition).
22 Testing sessions lasted about 30 minutes. In 
the rare case of seizures occurring during neuropsy-
chological examination, testing was suspended and data 
were not evaluated. 
3. Study design
We evaluated the differences in cognitive function, on 
the basis of subjective complaints and cognitive tests, 
between the TPM and OXC groups at 1 year. We also 
investigated the change in cognitive scores from baseline 
to 1 year of medication, in each group. We compared 
cognitive results with the patients’ characteristics, the 
clinical features of the epilepsy, EEG abnormalities, 
neuroradiological findings, and daily AED dosage. To Kim SY, et al. Cognitive Effects of Low-dose Topiramate in Epilepsy Patients 
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assess the effects of daily AED dosage on cognitive 
function, the frequency of cognitive complaints and the 
change in cognitive scores from baseline to 1 year of 
medication, at each target dose, were compared.
4. Statistical analysis
For nearly all the neuropsychological tests a higher 
score indicated a better performance; an exception was 
the TMT (parts A and B), where a lower score indicated 
a better performance because here the time required was 
defined as the dependent measure. The data for continuous 
variables are expressed as mean±SD values, and the data 
for categorized variables are expressed as frequencies. 
We used paired t  tests to compare cognitive scores 
before and after medication in the same subject. We also 
used  t  tests for independent samples to compare the 
cognitive scores of the TPM group with those of the 
OXC group. Fisher’s exact test was used for the 
categorized variables. A one-way analysis of variance 
(ANOVA) for independent samples was used for 
comparing differences of cognitive scores before and 
after AED medication among groups receiving different 
AED dosages. Bonferroni correction was employed for 
post-hoc comparisons, with an α  level set at 0.05.
RESULTS
1. Intra- and intergroup differences
At 1 year, as shown in Table 2, the TPM group 
showed worse performances of forward and backward 
digit span (P<0.01) and verbal fluency (P<0.01) com-
pared with baseline. The OXC group showed better 
performances of list learning (P<0.05), delayed word 
recall (P<0.05), and Trail Making Test parts A (P<0.05) 
and B (P<0.01). Patient groups were compared with 
respect to several neuropsychological tests done at 
baseline. As Table 2 indicates, their initial cognitive 
scores were not significantly different from each other. 
However, after 1 year of treatment the TPM group 
showed a significant difference in the performances of 
delayed word recall (P<0.05), backward digit span (P< 
0.01), and verbal fluency (P<0.05) compared to the 
OXC group. The differences in the performance of 
backward digit span and verbal fluency between groups 
were related to the worse performance of these tests in 
the TPM group due to a significant decrease in those 
scores after 1 year. On the other hand, the difference in 
the delayed word recall was due to the improved 
performance on this test by the OXC group over the 
course of treatment. 
The incidence of cognitive complaints was higher (P< 
0.05) in the TPM group (15/30 patients, 50%) than the 
OXC group (6/30 patients, 20%). Patients taking TPM 
described their cognitive complaints as memory deficit 
(50%), speech problems (30%), attention / concentration 
deficit (10%), and psychomotor slowing (7%). The 
severity of symptoms was expressed as Grade 1 in 12 
patients and Grade 2 in 3 patients. Patients taking OXC 
complained of memory deficit (17%) and attention / con-
centration deficit (3%), which were expressed as Grade 
1.
2. Correlational analyses
The frequency of cognitive complaints and changes in 
neuropsychological test scores in the TPM and OXC 
groups did not correlate with patient characteristics, 
clinical features of epilepsy, EEG abnormalities, or 
neuroradiologic findings. However, the frequency of 
cognitive complaints in the TPM group was significantly 
lower in patients taking 50 mg/day TPM (1/9 patients) 
than those taking 75 mg/day (7/10 patients), and 100 
mg/day (6/8 patients) (Fisher exact, P<0.05). One-way 
ANOVA revealed a significant interaction effect 
between the amount of daily TPM dosages and the 
differences in cognitive score before and after TPM 
medication on digit span forward (P<0.05), digit span 
backward (P<0.05), and verbal fluency (P<0.05) tests. 
After post-hoc comparisons, groups taking 100 mg/day 
and 200 mg/day TPM showed significant decreases in 
digit span and verbal fluency compared to those in the 
group taking 50 mg/day TPM (P<0.05). As shown in 
Fig. 1, the group prescribed 50 mg/day TPM did not 
show any significant change of scores on these tests at 
1 year.Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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Measure Test session
TPM (n=30)
mean (SD)
OXC (n=30)
mean (SD)
Significance*
List learning Baseline
At 1 year
56.1 (9.9)
56.8 (7.6)
57.0 (8.5)
59.4 (8.7)
‡
NS
†
NS
Immediate word recall Baseline
At 1 year
10.4 (1.9)
10.5 (1.6)
10.6 (1.7)
11.0 (1.2)
NS
NS
Delayed word recall Baseline
At 1 year
10.4 (1.9)
10.2 (1.7)
10.5 (1.9)
11.1 (1.1)
‡
NS
P<0.05
Word recognition Baseline
At 1 year
12.0 (0.2)
11.9 (0.3)
11.9 (0.3)
12.0 (0.0)
NS
NS
Visual reproduction Baseline
At 1 year
 7.8 (1.9)
 7.6 (2.2)
 7.7 (2.5)
 7.9 (2.1)
NS
NS
Digit span, forward Baseline
At 1 year
 8.0 (2.4)
 7.0 (2.8)
§
 8.2 (2.4)
 8.1 (2.4)
NS
NS
Digit span, backward Baseline
At 1 year
 6.5 (2.1)
 5.4 (2.5)
§
 6.7 (2.6)
 7.0 (2.3)
NS
P<0.01
Trail Making Test, part A
Time (sec)
Error no.
Baseline
At 1 year
Baseline
At 1 year
33.4 (13.7)
33.4 (13.0)
 0.2 (0.5)
 0.1 (0.3)
35.5 (22.4)
29.9 (22.7)
‡
 0.1 (0.4)
 0.1 (0.4)
NS
NS
NS
NS
Trail Making Test, part B
Time (sec)
Error no.
Baseline
At 1 year
Baseline
At 1 year
93.5 (49.4)
95.4 (49.7)
 0.7 (0.9)
 0.8 (1.1)
99.6 (80.1)
85.5 (71.4)
§
 0.9 (1.2)
 0.7 (1.2)
NS
NS
NS
NS
Verbal fluency Baseline
At 1 year
15.7 (3.9)
13.6 (4.4)
§
15.6 (4.3)
16.8 (5.6)
NS
P<0.05
TPM; topiramate, OXC; oxcarbazepine
*t tests for independent samples (two-sided), 
†Nonsignificant,  P>0.05, 
‡P<0.05, 
§P<0.01, paired t test for comparison with baseline. 
Higher scores indicate better performance except for Trail Making Test.
Table 2. Neuropsychological outcome 
DISCUSSION
This was the first comparative study between TPM 
and OXC demonstrating the cognitive dysfunctions of 
low-dose TPM (75~200 mg/day) in epileptic patients. 
After 1 year of treatment, the TPM group showed a 
significant difference in the performance on delayed 
recall, backward digit span, and verbal fluency compared 
with the OXC group. The incidence of cognitive com-
plaints was higher in the TPM group than in the OXC 
group. Low-dose TPM monotherapy had negative effects 
on attention/concentration and verbal fluency, although it 
reduced monthly seizure rate and EEG abnormalities to 
be related to the cognitive impairment. These cognitive 
effects were dose-related. Cognitive dysfunction was Kim SY, et al. Cognitive Effects of Low-dose Topiramate in Epilepsy Patients 
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Figure 1. Comparison of the difference in mean cognitive scores
before and after initiation of TPM medication among groups 
with different daily TPM dosages (50 mg, n=9; 75 mg, n=10; 
100 mg, n=8; and 200 mg, n=3). A significant interaction effect
on the digit span and verbal fluency tests is observed. A group
assigned to take 50 mg/day TPM did not exhibit any significant 
change in scores on these cognitive tests compared with other 
groups. DSF; digit span forward, DSB; digit span backward, VF;
verbal fluency. *P<0.05 (one-way ANOVA for independent
samples). 
trivial with patients taking 50 mg/day TPM. On the 
other hand, OXC has a positive effect on cognition such 
as list learning, delayed word recall, and TMT parts A 
and B.
Even though several studies have provided clinical 
evidence of TPM-induced cognitive impairment, their 
findings were limited by small numbers of patients, the 
absence of baseline cognitive assessments, intractable 
seizures, irregular TPM dosages, concurrent or previous 
AED use, or brain pathology.
6-14 To minimize these 
confounding factors, the ideal cognitive study should 
involve patients with newly diagnosed epilepsy on AED 
monotherapy, with cognitive assessments before treat-
ment, and at a point when the patients have been in 
steady-state treatment at a certain clinical dose.
26,27 
Our cases met these criteria and we somewhat eliminated 
several of the confounding factors in epilepsy. We 
selected patients who were taking monotherapy. A 
substantial portion of our cases were newly diagnosed 
and nonlesional. The majority of cases were well 
controlled by AED.
Another common methodology in studies of the 
cognitive effects of AEDs is a comparative one, in 
which the cognitive effects of the drug of interest is 
compared with other widely prescribed drugs. However, 
results of such studies can be obscured by differences in 
populations, seizure types, seizure frequency, duration of 
treatment, dosage, and background therapy (i.e., mono-
therapy or polytherapy).
25 Our study once again overcame 
these problems. Nevertheless, since this study was 
retrospective, it did have some inevitable methodological 
limitations. Patients were selected from our neuropsy-
chological database according to a set of self-generated 
inclusion criteria; selection bias therefore cannot be 
excluded, and so a future multicenter, double- blind, and 
placebo-controlled study would be invaluable.
As evident from the incidence of subjective com-
plaints, TPM is better tolerated at lower dosages. In 
recent monotherapeutic trials of TPM, the incidence of 
cognitive complaints ranged from 3% to 11% when 
using 25~500 mg/day TPM.
4,5,26 Compared to those 
trials, the incidence of cognitive complaints in our study 
was considerably higher (50%). In fact, the incidence in 
our study was even higher than that of a study using 400 
mg/day TPM as adjunctive therapy (where memory 
deficit was 18%, difficulty with concentration/attention 
was 9%, and language disorders were 12%).
10 These 
differences might have been due to ethnic variations 
because dosage requirements and the potential for toxic 
reactions to psychotropic medication can differ with race 
and ethnicity.
27 Our recommendation is that Asians 
should have their dosage of TPM adjusted more 
cautiously than is the case with Caucasians. Another 
possible explanation for the higher incidence of cognitive 
complaints in our study is that TPM patients in previous 
trials had had poor awareness of their cognitive 
dysfunction and so they may not have reported these 
problems spontaneously.
13 Therefore, specific questioning 
about cognitive problems and brief cognitive testing 
during patients’ clinic visits may be particularly 
important when managing TPM treatment. 
It remains to be elucidated whether there is any 
correlation between daily TPM dosages and cognitive 
impairment. Cognitive complaints tend to be dose- 
related;
5,26 however, performance on cognitive tests is 
not.
9,13 Our study showed that both indices were certainly Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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affected by daily TPM dosages of more than 50 mg. 
Data from controlled trials suggest that 100 mg/day 
TPM as monotherapy is effective for the treatment of 
epilepsy.
28 However, this does not mean that all patients 
will respond to this dosage and experience clinical 
benefit; lower or higher doses may better suit individual 
patients. Recently, a 59% seizure-free rate at 1 year 
using 50 mg/day TPM has been reported in patients with 
newly diagnosed epilepsy.
26  Among 9 patients who took 
50 mg/day TPM in our study, 7 patients became seizure- 
free at 1 year and most of them (6 of 7 patients) had 
been diagnosed as newly diagnosed epilepsy. Therefore, 
we recommend 50 mg/day TPM as a target dosage for 
the treatment of newly diagnosed epilepsy in order to 
minimize cognitive impairment.
Findings of significant changes in digit span can be 
considered a reflection of impaired attention / concen-
tration (i.e., working memory). Interestingly, our study 
showed that the learning and memory tests were not 
affected by TPM, despite a high incidence of memory 
complaints. This could mean that memory deficits are 
related to impairments in attention. Our patients mostly 
complained of short-term memory impairments such as 
holding in mind a spoken telephone number or address 
while they searched for a pencil and paper. Since the 
impairments of working memory and verbal fluency 
revealed by the current study reflect frontal lobe 
dysfunction,
13 further cognitive measures for this condi-
tion, probably involving neuroimaging techniques, might 
be useful in clarifying the pathophysiology of cognitive 
dysfunction induced by TPM. 
The OXC group in our study showed better per-
formances on attention and memory tests and less 
cognitive complaints than did the TPM group. The 
positive cognitive effects of using OXC may be related 
to its therapeutic effect on epilepsy, which lead to 
decreased psychosocial problems, or to stimulation of 
psychomotor functioning. In comparing OXC to placebo, 
a double-blind, low-dose, cross-over study with healthy 
volunteers indicated that OXC improved performance on 
both a focused attention task and on manual writing 
speed.
29 However, further studies are needed to elucidate 
its cognitive effect on epilepsy patients. 
Avoiding the harmful cognitive effects of AEDs is 
especially important to those requiring maximal cognitive 
efficiency for their job, school, or daily activities. Even 
low-dose TPM has a negative effect on short-term 
memory and verbal fluency compared with OXC, an 
effect that could compromise occupational functioning or 
academic achievement. Awareness of this risk, and 
careful monitoring of patients using TPM, will help 
minimize long-term problems. Lower dosages such as 50 
mg/day TPM could not only decrease the risk of signi-
ficant cognitive effects, but also maintain its efficacy. 
Further studies are needed to clarify the optimal daily 
dosage of TPM for maximizing treatment effectiveness 
and improving the patient’s quality of life, especially in 
newly diagnosed epilepsy. 
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